Delving into the Latest Updates on Scopolamine Butylbromide with Synapse

Gastrointestinal endoscopy procedures, including upper gastrointestinal endoscopy and colorectal endoscopy, represent a fundamental and important method for examining and managing digestive tract diseases, with both diagnostic and therapeutic applications. They are also utilized as effective tools for surveillance of gastrointestinal tumors. During upper gastrointestinal endoscopy procedures, gastric peristalsis may restrict the operative field of view and access, significantly affecting procedural precision. Excessive peristalsis not only affects the observation of simple lesions but also impacts other procedural maneuvers Therefore, during upper gastrointestinal endoscopy procedures, antispasmodic agents are commonly used to suppress gastrointestinal motility, ultimately facilitating endoscopic visualization. However, most antispasmodic agents, such as hyoscine butylbromide (Buscopan), cimetropium bromide (Algiron), and atropine, must be administered by injection. Intravenous or intramuscular administration causes patient pain and anxiety, and increases medical costs. Some researchers have taken an alternative approach by spraying L-menthol onto the gastric mucosa during gastroscopy to reduce gastric peristalsis. Although study results and adverse reaction profiles have demonstrated its superiority, the application process still presents operational inconveniences. Furthermore, these drugs should be used with caution as they may cause potential adverse reactions, including dry mouth, urinary retention, temporary impairment of visual accommodation, palpitations, anaphylactic shock, and hyperglycemia.

Start Date01 Dec 2025

Sponsor / Collaborator

Shanghai Jiao Tong University School of Medicine

ISRCTN10543404

/ RecruitingNot ApplicableIIT

Investigating the effects of oral scopolamine on cognition and emotion processing

Start Date18 Nov 2025

Sponsor / Collaborator

University of Oxford

ChiCTR2500106601

/ Not yet recruitingNot ApplicableIIT

Exploring the inhibitory effect of scopolamine butylbromide on TSM artifacts in liver gadoxetate disodium‌-enhanced magnetic resonance imaging

Start Date01 Jun 2025

Sponsor / Collaborator

Southwest Hospital, China

100 Clinical Results associated with Scopolamine Butylbromide

Login to view more data

100 Translational Medicine associated with Scopolamine Butylbromide

Login to view more data

100 Patents (Medical) associated with Scopolamine Butylbromide

Login to view more data

904

Literatures (Medical) associated with Scopolamine Butylbromide

01 May 2025·MAGNETIC RESONANCE IMAGING

Use of deep learning-accelerated T2 TSE for prostate MRI: Comparison with and without hyoscine butylbromide admission

Article

Author: Valentin, B ; Drewes, L ; Wittsack, H J ; Antoch, G ; Radtke, J P ; Albers, P ; Boschheidgen, M ; Ullrich, T ; Trappe, S ; Al-Monajjed, R ; Schimmöller, L

OBJECTIVE:

To investigate the use of deep learning (DL) T2-weighted turbo spin echo (TSE) imaging sequence with deep learning acceleration (T2DL) in prostate MRI regarding the necessity of hyoscine butylbromide (HBB) administration for high image quality.

METHODS:

One hundred twenty consecutive patients divided into four groups (30 for each group) were included in this study. All patients received a T2DL (version 2022/23) and a conventional T2 TSE (cT2) sequence on an implemented 3 T scanner and software system. Group A received cT2 with HBB compared to T2DL without HBB with a field of view (FOV) of 130 mm and group B with a FOV of 160 mm. Group C received both sequences with a FOV of 160 mm plus HBB and group D without HBB. Two radiologists independently evaluated all imaging datasets in a blinded reading regarding motion, sharpness, noise, and diagnostic confidence. Furthermore, we analyzed quantitative parameters by calculating edge rise distance (ERD), signal-to-noise-ratio (SNR), and contrast-to-noise-ratio (CNR). Friedman test was used for group comparisons.

RESULTS:

Baseline characteristics showed no significant differences between groups A-D. After HBB cT2 showed less motion artifacts, more sharpness, and a higher diagnostic confidence than T2DL, though DL sequences had significantly lower noise (p < 0.01). Quantitative analysis revealed higher SNR and CNR for T2DL sequences (p < 0.01), while edge rise distance (ERD) remained similar. Inter-reader agreement was good to excellent, with ICCs ranging from 0.84 to 0.93. T2DL acquisition time was significantly lower than for cT2.

CONCLUSIONS:

In our study, cT2 sequences with HBB showed superior image quality and diagnostic confidence while the T2DL sequence offer promising potential for reducing MRI acquisition times and performed better in quantitative measures like SNR and CNR. Additional studies are required to evaluate further adjusted and developed DL applications for prostate MRI on upcoming scanner generations and to assess tumor detection rates.

25 Apr 2025·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

Treatment of Irritable Bowel Syndrome with Predominant Diarrhea

Review

Author: Kim, Min Cheol ; Park, Yehyun ; Lee, Hong Sub

Irritable bowel syndrome with predominant diarrhea (IBS-D) is a subtype of irritable bowel syndrome that causes frequent loose stools. Although the precise pathophysiology remains unclear, factors, such as gut microbiota imbalance, visceral hypersensitivity, intestinal permeability changes, and stress, play significant roles. Recent studies have suggested that dysbiosis is a key contributor to IBS-D pathogenesis, emphasizing the need for targeted therapeutic strategies. The treatment of IBS-D involves pharmacological and non-pharmacological approaches. Pharmacological treatments include antidiarrheal agents, such as loperamide, which reduce stool frequency but have limited effects on pain relief. Antispasmodics, such as octylonium bromide and hyoscine butylbromide, alleviate abdominal pain by modulating intestinal motility. Rifaximin, a non-absorbable antibiotic, has shown efficacy in symptom reduction by altering the gut microbiota. Selective serotonin receptor antagonists, such as ramosetron, have benefits in symptom control, particularly in male patients. In addition, low-dose tricyclic antidepressants help manage pain and stool irregularities by modulating the gut-brain interactions. Non-pharmacological strategies include dietary modifications, with the low-FODMAP diet showing potential benefits despite concerns about long-term nutritional adequacy. Psychological interventions, such as cognitive behavioral therapy and gut-directed hypnotherapy, are recommended for patients with persistent symptoms unresponsive to medication. Mild physical activities, such as yoga and walking, relieve symptoms by improving gut motility and reducing stress. Personalized treatment approaches are essential because IBS-D presents a wide spectrum of symptoms. Clinicians should tailor therapeutic plans based on individual patient characteristics, balancing the benefits and risks of each intervention to optimize symptom control and improve the quality of life.

01 Apr 2025·PLANT BIOTECHNOLOGY JOURNAL

Multi‐omics analysis identified the GmUGT88A1 gene, which coordinately regulates soybean resistance to cyst nematode and isoflavone content

Article

Author: Teng, Weili ; Han, Yingpeng ; Li, Yongguang ; Jiang, Haipeng ; Zhan, Yuhang ; Sun, Haowen ; Li, Haiyan ; Qu, Shuo ; Liu, Fang ; Zhao, Xue

Summary:

Soybean cyst nematode (SCN, Heterodera glycines) is a major pathogen harmful to soybean all over the world, causing huge yield loss every year. Soybean resistance to SCN is a complex quantitative trait controlled by a small number of major genes (rhg1 and Rhg4) and multiple micro‐effect genes. Therefore, the continuous identification of new resistant lines and genes is needed for the sustainable development of global soybean production. Here, a novel disease‐resistance quantitative trait locus Rscn‐16 was identified and fine mapped to an 8.4‐kb interval on chromosome 16 using an F2 population. According to transcriptome and metabolome analysis, a UDP‐glucosyltransferase encoding gene, GmUGT88A1, was identified as the most likely gene of Rscn‐16. Soybean lines overexpressing GmUGT88A1 exhibited increased resistance to SCN, higher isoflavone glycosides and larger seed size while the phenotype of RNA‐interference and knockout soybean lines showed sensitivity to SCN and decreased in seed size compared to wild‐type plants. GmMYB29 gene could bind to the promoter of GmUGT88A1 and coordinate with GmUGT88A1 to regulate soybean resistance to SCN and isoflavone accumulation. Under SCN infection, GmUGT88A1 participated in the reorientation of isoflavone biosynthetic metabolic flow and the accumulation of isoflavone glycosides, thus protecting soybean from SCN stress. GmUGT88A1 was found to control soybean seed size by affecting transcription abundance of GmSWEET10b and GmFAD3C, which are known to control soybean seed weight. Our findings provide insights into the regulation of SCN resistance, isoflavone content and seed size through metabolic flux redirection, and offer a potential means for soybean improvement.

28

News (Medical) associated with Scopolamine Butylbromide

31 Dec 2025

·www.pharmaceutical-technology.com

FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus

Up to 78 million adults in the US are estimated to be affected by motion sickness. RealPeopleStudio via Shutterstock.com. The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting induced by motion. Nereus, taken as an oral capsule, is a new option to those who suffer from motion sickness, becoming the first pharmacological-based therapy to win the agency’s greenlight in this indication in over four decades. The US-based pharma company aims to launch the drug in the coming months. Up to 78 million adults in the US are estimated to be affected by motion sickness, with symptoms usually presenting during transport in cars, planes, and boats. It arises from a sensory conflict between the eyes, inner ear, and proprioceptors. The mixed neural signals result in disorientation and nausea mediated by a chemical called substance P. Nereus works by inhibiting NK-1 receptors – the target of substance P. The FDA based its decision on three pivotal clinical trials, two of which were Phase III real-word studies conducted on boats. Nereus significantly reduced the incidence of vomiting compared to placebo. Vanda’s CEO Mihael Polymeropoulos said: “For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology, offering effective prevention without the limitations of existing options.” Many patients administer over-the-counter pills and patches to counteract motion sickness, though prescription therapies are needed for recurrent and more severe symptoms. Viatris’ scopolamine patch, known under the brand name Transderm Scop, is one such prescription medicine. The FDA first approved scopolamine in 1979, with the drug now a central pillar of the motion sickness treatment space. Defender Pharmaceuticals hoped to enter the market with a nasal gel version of scopolamine, though the FDA rejected the candidate in January 2024. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Vanda is already eyeing further indications for tradipitant. The drug is in the regulatory stage for gastroparesis, a chronic disorder characterised by delayed gastric emptying and persistent nausea and vomiting. The FDA rejected Vanda’s application for tradipitant in gastroparesis in September 2024, citing a lack of substantial evidence of effectiveness and safety. Tradipitant is also in clinical development for the prevention of nausea and vomiting induced by glucagon like peptide receptor agonists (GLP-1RAs) – a drug class that has boomed in popularity in the diabetes and weight loss sectors. In November 2025, the company announced positive results from a Phase II study. Pharmaceutical Technology Excellence Awards - Nominations Closed Nominations are now closed for the Pharmaceutical Technology Excellence Awards . A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact. Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing , Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines. Discover the Impact

Clinical ResultDrug ApprovalPhase 3Phase 2

07 Jul 2025

·www.pharmamanufacturing.com

EU fines Alchem $525K for price-fixing of key active pharmaceutical ingredient

Alchem International, an India-based manufacturer of pharmaceutical ingredients, and its Hong Kong subsidiary have been fined €489,000 (approximately $525,000) by the European Commission for violating antitrust rules related to active pharmaceutical ingredient (API) pricing. According to the Commission, Alchem participated in a long-running cartel involving N-Butylbromide Scopolamine/Hyoscine (SNBB), a key API used in the production of Buscopan and its generic equivalents. From November 2005 through February 2018, the company worked with competitors to set minimum sales prices, allocate customer quotas, and exchange commercially sensitive information across the European Economic Area. The European Commission stated that Alchem’s behavior constituted a single and continuous infringement. The company chose not to cooperate with the investigation, unlike other participants that settled in 2023. As a result, Alchem did not receive any fine reductions under the EU’s leniency or settlement programs. The fine was based on the value of SNBB sales during the infringement period, along with the geographic scope and duration of the violation, according to the announcement. This case represents the first time the European Commission has penalized a cartel involving an active pharmaceutical ingredient. The investigation was initiated by a 2019 leniency application from C2 PHARMA and was supported by competition authorities in Switzerland and Australia. The European Commission noted that individuals or companies harmed by the cartel’s behavior may pursue damages through national courts within EU member states.

Patent Infringement

06 Jul 2025

·endpoints.news

European Commission fines Alchem, closes API ‘cartel’ investigation

The European Commission has found Alchem guilty of participating in a drug ingredient “cartel” for more than a decade after the drugmaker previously chose not to settle in an investigation. The agency fined Alchem €489,000 ($575,000) after finding that the company had illegally fixed the price of an API, known as N-butylbromide scopolamine/hyoscine (SNBB), used in the production of Buscopan, a drug used to treat stomach cramps. The EC found that the company had “illegally coordinated prices” and “allocated quotas” for more than 12 years, according to a Friday release . “Today’s decision marks the end of our investigation into the SNBB cartel,” said Teresa Ribera, EVP for Clean, Just and Competitive Transition at the EC. In a first, the EC in October 2023 fined several companies — Alkaloids of Australia, Alkaloids Corporation, Boehringer Ingelheim, Linnea and Transo-Pharm — a total fine of $13.4 million for being involved in a “cartel” to illegally fix the price of SNBB. At that time, New Delhi-based Alchem was the only company that chose not to cooperate or settle with the EC, so the agency had to continue its investigation . The inquiry was initially triggered by a notice to the EC in 2019 by C2 Pharma. It was not fined because it warned the agency of the illegal operations.

100 Deals associated with Scopolamine Butylbromide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00138	Scopolamine Butylbromide	S01FA02 N05CM05 A04AD01	DB09300

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Gastrointestinal spasm	Australia	Sanofi /Consumer Healthcare Products/	26 Sep 1991
Renal Colic	Australia	Sanofi /Consumer Healthcare Products/	26 Sep 1991
Spasm biliary	Australia	Sanofi /Consumer Healthcare Products/	26 Sep 1991
Motion Sickness	United States	Baxter Healthcare Corp.	31 Dec 1979
Postoperative Nausea and Vomiting	United States	Baxter Healthcare Corp.	31 Dec 1979
Habit Spasms	Japan	Sanofi KK	17 Mar 1955

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Intestinal Diseases	Phase 3	China	Boehringer Ingelheim GmbH	01 Aug 2013
Abdominal Pain	Phase 3	-	Boehringer Ingelheim GmbH	01 Nov 2008
Gastralgia	Phase 3	-	Boehringer Ingelheim GmbH	01 Nov 2008
Colic	Phase 2	-	Boehringer Ingelheim GmbH	01 Apr 2006
Muscle Cramp	Phase 2	-	Boehringer Ingelheim GmbH	01 Apr 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00932737 (CTgov)	Phase 2	Abdominal Pain \| Muscle Cramp	197	Placebo	dqlahwyqnc(qmrxbyddqz) = mxnwqfjwxz oupfzivren (pergfjetbm, 3.10) View more	-	03 May 2022
NCT03430362 (not provided, Pubmed \| Arch Gynecol Obstet)	Not Applicable	-	100	Hyoscine butyl bromide (HBB)	pvnviwbfqo(xejdnzkqon) = trnepztcjz bvkxfyuoog (aoyvxmrqgj )	-	13 May 2021
				Normal saline	pvnviwbfqo(xejdnzkqon) = hylrbflspe bvkxfyuoog (aoyvxmrqgj )
NCT02582307 (Pubmed \| CMAJ)	Phase 3	Colic	236	Hyoscine butylbromide	qqhyakqfoq(auknblsyeb) = mevkxecxzb jtmaxzuxpn (dmoituapvg ) View more	-	30 Nov 2020
				Acetaminophen	qqhyakqfoq(auknblsyeb) = zabszgzwof jtmaxzuxpn (dmoituapvg ) View more
NCT01734902 (CTgov)	Phase 1	-	30	Hyoscine Butylbromide (Hyoscine Butylbromide Drops (T))	iiwpmddksd(syhtkuwlhp) = ctpmyxdeua ymmhixnshf (ktanjbxsac, 140.0) View more	-	23 Apr 2019
				Buscopan (Buscopan® Tablet (R))	iiwpmddksd(syhtkuwlhp) = jfbvcorezi ymmhixnshf (ktanjbxsac, 167.0) View more
NCT03029650 (CTgov)	Phase 4	-	26	Transderm Scop® (Transderm Scop®)	khlbmgudxs(hpbxoprjqo) = meokqzkqdn sycfsdibet (hdbthrsrqv, 0.08) View more	-	21 Jun 2018
				Transderm Scop® (Intravenous Scopolamine Hydrobromide)	khlbmgudxs(hpbxoprjqo) = psehtkhtag sycfsdibet (hdbthrsrqv, 1.02) View more
NCT02242305 (CTgov)	Phase 3	Abdominal Pain \| Gastralgia	302	Placebo+Hyoscine Butylbromide - Tablet (Hyoscine Butylbromide - Tablet)	hirssipgzz = etvfmnvitp vehddkyarp (yqmuovwher, dawschjrfd - ulaxbowjvt) View more	-	27 Jul 2017
				Placebo+Hyoscine Butylbromide - Capsule (Hyoscine Butylbromide - Capsule)	hirssipgzz = gouxlsipjj vehddkyarp (yqmuovwher, fzxvkvaaue - vhfnnqbobq) View more
NCT02516098 (CTgov)	Phase 1	-	56	Buscopan (Buscopan® (REF))	ehivbprajg(kyscozdtot) = rhsabjhgdq qhjdlllojo (pgpmbcvqqw, 93.4) View more	-	13 Feb 2017
				Buscapina (Buscapina® (T))	ehivbprajg(kyscozdtot) = ikwzzmeqqm qhjdlllojo (pgpmbcvqqw, 100.6) View more
NCT01929044 (CTgov)	Phase 3	Intestinal Diseases \| Gastralgia	299	Buscopan® (hyoscine butylbromide)	oonltjnaib(ehlxyegifi) = iwrzudfqdl jzejgklzdr (jvikfqyhzo, 0.17) View more	-	08 Mar 2016
NCT01281501 (CTgov)	Phase 4	Dyspepsia \| Acute Pain \| Acid dyspepsia	87	Hyoscine butylbromide+Oral antacid+Normal saline (Conventional)	zvtxpafgtg(gxrvsasdxv) = agqxdxiein irekceishf (pbwzlodmlw, 24) View more	-	27 Jul 2012
				Hyoscine butylbromide+Oral antacid+Pantoprazole (Pantoprazole)	zvtxpafgtg(gxrvsasdxv) = kpklzvcmoh irekceishf (pbwzlodmlw, 23) View more
ISRCTN25405865 (Pubmed \| Gastrointest Endosc)	Not Applicable	-	674	Hyoscine N-butylbromide	shqxewkmep(kbnxqfvsft) = rtobfxlnzl lhulqvvuhk (jzxvmpjvhj ) View more	Negative	01 Apr 2012
				Placebo	shqxewkmep(kbnxqfvsft) = snrlwlzuui lhulqvvuhk (jzxvmpjvhj ) View more